CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 target
Drug / intervention
Aripiprazoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00305370
NCT00305370Phase 4Completed

Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD: A Randomized Cross-Over Placebo Controlled Trial

Federal University of Rio Grande do Sul·interventional·Posted Mar 21, 2006·Updated Aug 7, 2008

In Brief

A Phase 4 clinical trial evaluating Aripiprazole for Bipolar Disorder and Attention Deficit Hyperactivity Disorder. Completed, enrolled 20 participants across 1 site.

Detailed Summary

There is a scarcity of clinical trials assessing the effects of medications in children with bipolar disorder. This study aims to assess the efficacy of Aripiprazole associated with Methylphenidate (MPH)for the treatment of children and adolescents with bipolar disorder comorbid with ADHD who improve in maniac symptoms while receiving aripiprazole but did not have an adequate response in ADHD symptoms. The study design is a 4-week randomized, double blind, cross-over group trial. Patients were randomized to aripiprazole + MPH or aripiprazole + placebo. The main hypothesis is: Aripiprazole + MPH will significantly reduce ADHD scores compared to aripiprazole + placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBrazil
Collaborators--

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 21, 2006
Enrollment StartAug 1, 2005
Primary CompletionJan 1, 2008
Study CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 20.3 years ago

Interventions

Aripiprazoledrug